T he Maternal Phenylketonuria Collaborative Study (MPKUCS) was started in 1984 and has been described in several previous publications. [1] [2] [3] [4] [5] During the course of this study, stringent efforts have been made to ascertain the phenylalanine hydroxylase (PAH) mutations underlying PAH deficiency in each proband and to determine which mutation was carried by her offspring. At the same time, each pregnancy was studied prospectively with a standard protocol that included the Wechsler Adult Intelligence Scale-Revised (WAIS-R), current blood phenylalanine levels as well as untreated phenylalanine levels, and various biochemical parameters.
One of the primary factors determining the reproductive outcome in maternal phenylketonuria (PKU) is the phenylalanine-restricted dietary control that is somewhat dependent on the cognitive skills of the mother. 6 A previous study has established the mutational spectrum responsible for PAH deficiency in females enrolled in the MPKUCS. 7 The aim of the present study was to examine to what extent the PAH genotype is related to the biochemical phenotype and, in particular, to what extent this relationship influences the cognitive development of females with PKU and therefore may influence the reproductive outcome in maternal PKU.
PATIENTS, MATERIALS, AND METHODS

Patients
The organization of the MPKUCS has been described previously. 8 Data on 222 hyperphenylalaninemic females enrolled in the MPKUCS were contributed by 110 clinics in the three countries involved. The data were compiled and prepared for statistical analyses at the Division of Medical Genetics, Children's Hospital, Los Angeles, California. Informed consent for enrollment in the study was obtained on each enrollee by the coordinator or geneticist caring for each pregnancy.
Materials
Routine, weekly measurements of phenylalanine levels were performed using primarily the McCaman and Robins fluorometric method 9 or, occasionally, the Guthrie bacterial inhibition assay. 10 Plasma amino acids were determined each trimester by the amino acid analyzer. 11 An assigned blood phenylalanine level was calculated on each proband 2 by recording values of three blood samples obtained on a normal diet on different days. The highest value was designated the assigned phenylalanine level (APL). The cognitive performance was determined after 18 years of age by means of the WAIS-R in a standardized manner. Data on parental cognitive abilities were not available.
Methods
Blood for PAH genotyping was obtained by venipuncture and airmailed at room temperature to The John F Kennedy Institute, where the genotyping was performed as described previously. 7 The general approach was simultaneous amplification of all PAHcoding genomic DNA regions in 13 individual polymerase chain reactions, followed by one-step scanning for mutations by broadrange denaturing gradient gel electrophoresis, 12 and direct sequence analysis of samples showing an altered electrophoretic mobility pattern.
Statistical Methods
One-way ANOVA was used to compare each of the dependent variables (APL, IQ) in the genotype groups. When the F value for testing the null hypothesis of no difference among the four means was statistically significant (P Ͻ .05), the two-sample t test with Bonferroni adjustment for multiple comparisons was applied to all possible pairs of groups to determine which groups differed. Two-way ANOVA with interaction was used to evaluate the effect on IQ of genotype classification and treatment history (discontinued early, late treated, or untreated in contrast with early treatment and treatment continued beyond 72 months of age).
Classification of Mutations
The four arbitrary phenotype categories (severe PKU, moderate PKU, mild PKU, and mild hyperphenylalaninemia [MHP]) have been described thoroughly previously. 11, 13, 14 Mutations that are known or predicted to abolish PAH activity completely (null mutations) were assigned as severe PKU mutations, as were mutations that have been identified previously in patients with severe PKU. Mutations that did not fulfill either of these criteria were assigned to one of the three other phenotype categories based on the phenotypic characteristics of each mutation observed in functionally hemizygous patients.
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RESULTS
Blood for genotyping was obtained in 222 probands. A potential causative mutation was identified on 416 (94%) of the mutant alleles, and the complete genotype was ascertained in 199 (90%) of the probands. A total of 84 different mutations were identified, most of which were described in detail in a previous report. 7 Additional mutations identified subsequently include K274del11bp, IVS7nt6t3a, IVS8nt-7a3g, T92I, and A395G.
Classification of Mutations
Among the 84 different mutations identified in the present study, 26 are known or predicted to abolish PAH enzyme activity completely and were assigned accordingly as severe PKU mutations (Table 1) . These mutations include six base substitutions that introduce a premature stop codon, eight frameshift mutations, seven mutations affecting the invariant AG-GT dinucleotides of splice sites, one additional splice site mutation (IVS10nt-11g3a), and four missense mutations (R252W, P281L, S349P, and R408W) that have shown zero enzyme activity when studied in in vitro systems. A total of 21 additional mutations were assigned as severe PKU mutations, because S16fsdelCT  K274del11bp  F39L  L48S  S87R  G148S  IVS1nt5g3t  E280K  I65T  R68S  T92I  P175A  G41F  P281L  E6nt-96A3g  delI94  D145V  P211T  F55fsdelT  IVS7nt1g3a  L249F  A104D  V177L  L213P  IVS2nt1g3a  IVS7nt5g3a  R261Q  IVS4nt-5c3g  E178G  A309V  T81P  IVS7nt6t3a  L348V  R241H  R241C  K320N  D84Y  F299C  V388M  Y277D  V245A  R111X  IVS8nt1g3a  L347F  A300S  IVS4nt-1g3a  IVS8nt-7a3g  R408Q  T380M  N133Q134fsdel4bp  IVS9nt6t3a  Y414C  E390G  R158Q  F331C  A395G  R158W  S349P  A403V  R176X  IVS10nt3a3g  D415N  W187X  IVS10nt-3c3t  P211fsdelC  IVS10nt-11g3a  G218V  Y356X  E221D222fsdelAG  K363fsdelG  R243Q  A395P  R243X  R400fsdelA  V245L  IVS11nt1g3a  R252Q  IVS11nt20g3c  R252W  R408W  R270K  IVS12nt1g3a  G272X  A447D * Mutations are classified according to a 4-level scheme based on the phenotypic characteristics of each mutation as observed in functionally hemizygous patients. 15 † MHP, mild hyperphenylalaninemia.
they have been identified previously in patients with severe PKU. 15 Among the remaining mutations, 31 could be assigned as either moderate or mild PKU, or MHP mutations based on previously observed phenotype characteristics of functionally hemizygous patients. 7, 15 Six mutations remained unclassified (Table 1) .
Relationship Between Genotype and Assigned Phenylalanine Level
Complete data on genotype and APL were available in 189 probands. Table 2 shows mean APL for women with various combinations of mutation classifications. The only groups with sample sizes large enough for statistical testing are represented in the first row, ie, 169 individuals with at least one severe PKU mutation. ANOVA showed significant differences in assigned phenylalanine level among these four groups (P ϭ .0001). Pairwise comparisons were significantly different between all pairs of groups, except that the group with a severe ϩ severe combination of mutations and the group with a severe ϩ moderate combination of mutations did not differ.
Relationship Between Genotype and Cognitive Performance
IQ on the WAIS-R scale was available in 164 probands after 18 years of age. A recent study has shown that IQ remains stable after 12 years of age, independent of dietary control. 16 Table 3 shows mean IQ (WAIS-R) for women with various combinations of mutation classifications. Again, the only groups with sample sizes large enough for statistical testing were those comprising 147 individuals with at least one severe PKU mutation (given in the first row of Table  3 ). ANOVA showed significant difference in IQ among these groups (P ϭ .0001). All pairs were significantly different, except that the group with a severe ϩ severe mutation combination and the group with a severe ϩ moderate mutation combination did not differ and the group with a mild ϩ severe combination of mutations and a MHP ϩ severe combination of mutations did not differ also. Mothers with a severe mutation on both PAH alleles demonstrated a mean IQ of 82.9 Ϯ 12.7 SD, whereas mothers carrying one severe mutation and one mild mutation demonstrated a mean IQ of 95.6 Ϯ 13.8 SD. By comparison, mothers carrying a severe mutation and a MHP mutation showed a mean IQ of 98.8 Ϯ 14.7 SD.
Relationship Between Treatment History and Cognitive Performance
Complete data consisting of the genotype, APL, age in months at initial diagnosis, age in months at first dietary treatment, and age in months when dietary treatment stopped were available in 147 probands. Of 123 females with PKU, 40 were treated late (Ͼ1 month) or were untreated (Table 4) . As expected, mean IQ scores of these 40 PKU females grouped by genotype were lower than average for the respective groups, and PKU females with the lowest IQ scores were found in these groups (40, 55, and 72). Surprisingly, five late treated females with two severe mutations and a mean APL of 28 mg/dL had a mean IQ of 96, and four late treated females with moderate PKU and a mean APL of 23 mg/dL had a mean IQ of 94.
Of 123 females with PKU, 26 were early treated and treated for Ͼ6 years. Their average IQ score was significantly higher (P ϭ .02) than was the average for those who were treated late, untreated, or discontinued early. This pattern was observed in all genotype groups and was most pronounced in the moderate and mild groups (Table 4) .
DISCUSSION
The PAH deficiency trait is heterogeneous at the biochemical level with a continuum of metabolic phenotypes that can be divided arbitrarily into four categories: severe PKU, moderate PKU, mild PKU, and non-PKU MHP. 11, 14, 17 These biochemical categories of PAH deficiency are valuable from a therapeutic point of view, because they indicate how much phenylalanine a given patient can tolerate per day. Several studies have suggested that the great phenotypic variability of PAH deficiency is correlated directly with allelic heterogeneity at the PAH locus.
14,15,18 -23 Now, Ͼ325 different disease-associated PAH gene mutations have been reported to the PAH Mutation Analysis Consortium Database (http:// www.mcgill.ca/pahdb).
In a recent European multicenter study, we have assessed the intrinsic severity of 105 different PAH mutations, and we have documented a simple relation between phenylalanine tolerance and the combination of inherited PAH mutations, in that the less deleterious of two mutations determines the phenotypic outcome. 15 Data from the present study show that the same relation exists between PAH genotype and biochemical phenotypes. In mothers with PKU with at least one severe PAH mutation, the biochemical phenotype predicted from the genotype was related significantly to the untreated blood phenylalanine levels; however, there are overlaps between the different categories of mutation combinations. There are several possible explanations for inconsistency between genotype and biochemical phenotype in some individuals, including combined heterozygosity for PAH mutations and mutation in another gene controlling phenylalanine metabolism and homeostasis. 24 However, variance in blood sampling related to the time and content of the last meal may be the most obvious reason for the overlaps in APL observed within the different genotype categories.
The most interesting finding in this study is the significant relation between genotype and cognitive performance. Two previous studies have compared genotype with biochemical phenotype and intellectual outcome in well-treated patients followed during the first 9 years of life. 19, 25 In one study, there was a correlation between genotype and untreated plasma phenylalanine levels in patients with severe PKU, moderate PKU, and mild PKU. The mean IQ scores (the German version of the WISC and WISC-R) were 93 in patients with two null mutations, 85 in patients with a moderate genotype, and 97 in patients with a mild genotype. 19 LichterKonecki et al 25 found that genotype was related to the degree of fluctuation in phenylalanine levels reflected by the SD of phenylalanine concentrations measured during the first 9 years of life and the SE of the mean for each individual. Although the mean serum phenylalanine level was identical in patients carrying mutations causing severe PKU compared with patients carrying mutations causing mild PKU, the mean IQ was significantly higher in patients with mild PKU. A significant correlation was found among genotype, fluctuations in individual phenylalanine levels, and IQ. Fluctuations of phenylalanine levels in patients with severe PKU and a more even plasma phenylalanine profile in patients with mild PKU are a general observation. Lichter-Konecki et al 25 concluded that because there is a correlation between parameters reflecting fluctuations in individual phenylalanine values and the IQ of the patient, an indirect influence of genotype on cognitive development is possible. The present study supports this hypothesis.
The present study shows that apart from an indirect influence of PAH genotype, other factors determine cognitive development and function, such as early or late initiation of dietary treatment and termination of dietary treatment. One important factor is probably the background genetic disposition for cognitive development, 26, 27 eg, parents' IQ, and another factor is the diet. These factors may explain the broad range of IQ scores observed in all genotype groups, including MHP, and may also be of relevance to the observation that some of the late treated females with PKU with two severe mutations or a severe plus a moderate mutation had IQ scores equal to those females who were treated early. These females may represent resilience to high phenylalanine levels. It will be interesting to see whether their children have inherited their mothers' genetic disposition for cognitive development. We have observed previously that three women, who were well integrated in the community and who were found to have unrecognized PKU, following planned pregnancies, had children with relatively high IQ scores, ϳ50 points above the index case (first child). 28 Females with moderate PKU or mild PKU who were treated early and treated for Ͼ6 years had IQ scores 10 points higher than the average for all pa- Tables 2 and 3. tients with the same combination of mutations. This observation stresses the upcoming policy of maintaining dietary therapy throughout adulthood in girls with PKU to improve intellectual functioning and to alleviate some of the difficulties encountered in returning to the diet and coping with life stresses during planned pregnancies. 29 The conclusion from the present study of women with PKU is that IQ decreases with increasing severity of genotype and also with delay of treatment or early termination of diet in childhood. The relationship of genotype to IQ suggests that females with severe or moderate PKU who are planning a pregnancy may have more difficulty in getting their blood phenylalanine levels within the recommended range, thus causing a lowering of IQ in the offspring. These women will need greater assistance to have a well treated pregnancy. An additional study to validate the possible relation between maternal genotype, IQ, and reproductive outcome is in progress. The question of whether the mutation inherited by the fetus has any effect on offspring outcome must await additional data collection.
